leaptx.com (LPTX) - Gross Sales Margin

Official company branding of leaptx.com (LPTX)

The average gross margin reflects the financial standing of Leap Therapeutics, Inc. (LPTX), which develops antibodies for gastrointestinal therapy without current operating profit. The value of 0.00 represents the current figure for this metric. The development of DKN-01 establishes a unique intellectual property base for the company, yet testing costs are creating a liquidity deficit and necessitating a constant influx of external financing to cover negative cash flow.

Leap Tx (LPTX) - Gross Margin from 07/04/2022 to 11/13/2025

Analytical breakdowns and data insights for company Leap Tx (LPTX)

- stock value and consensus price forecast:
- cash balance and cash flow data:
Fundamental valuation:Leap Therapeutics, Inc.
Signature product of Leap Therapeutics Inc

Leap Therapeutics, Inc. (LPTX) focuses on developing innovative antibodies for targeted oncology, making the gross sales margin a key performance indicator for the commercialization of the DKN-01 drug. This metric is calculated as the portion of revenue minus direct production costs, allowing investors to assess the business's internal profitability and the company's ability to generate excess capital for further scaling of development.